Perrigo Finding Balance As Three-Legged Stool With Two Consumer Units, Rx Division

As new CEO Uwe Röhrhoff plans a "value creation" analysis, the improving Rx business growth could be essential for company because US competition from smaller, online brands is increasing in the OTC drug space and its sales of its consumer health products in Europe have yet to reach expectations.

The outlook for Perrigo Co. PLC's Rx generics business could be on an upswing with the firm forecasting stronger growth in 2018 for the division than for its core businesses, its domestic and international consumer health product units.

The prospects for the Rx business have been questioned for the past year by both analysts and activist investors

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Marketing & Advertising

More from Compliance